ASX:RAC Race Oncology - RAC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Race Oncology Limited Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume76,322 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlines About Race Oncology (ASX:RAC) StockRace Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.Read More Receive RAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAC Stock News HeadlinesMarch 27, 2023 | proactiveinvestors.com.auRace Oncology galvanised for new research and development thanks to A$1.48 million tax refundMarch 24, 2023 | fool.com.auWhy is ASX All Ords healthcare share Race Oncology plummeting 10% today?March 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 24, 2023 | msn.comWhy Block, Mincor, Race Oncology, and Weebit Nano shares are sinking todayMarch 14, 2023 | proactiveinvestors.com.auRace Oncology poised for observational heart protection breast cancer trialMarch 12, 2023 | proactiveinvestors.comRace Oncology executes contract to begin observational heart protection breast cancer trialMarch 2, 2023 | proactiveinvestors.comRace Oncology higher on initiating collaboration to understand Zantrene’s cardioprotection mechanismMarch 1, 2023 | finance.yahoo.comInvesting in Race Oncology (ASX:RAC) three years ago would have delivered you a 548% gainMarch 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastFebruary 21, 2023 | bbc.comBreaking Through in Advanced Prostate CancerFebruary 20, 2023 | msn.comRace brings in new CEO as it looks beyond the clinic for potential partners and investorsFebruary 11, 2023 | msn.comRadioligand therapy, a 'game-changer' for cancer treatment, forces manufacturers to race against a ticking clockFebruary 9, 2023 | proactiveinvestors.com.auRace Oncology is moving in the right direction: Pitt Street ResearchFebruary 1, 2023 | proactiveinvestors.comRace Oncology receives human ethics approval for Zantrene trialDecember 22, 2022 | proactiveinvestors.com.auRace Oncology makes strong preclinical and clinical progress in 2022December 22, 2022 | proactiveinvestors.comRace Oncology to invest US$500,000 in University of Texas cancer imaging studyDecember 15, 2022 | proactiveinvestors.com.auRace Oncology welcomes veteran Damian Clarke-Bruce as managing director/CEODecember 15, 2022 | proactiveinvestors.com.auRace Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEODecember 13, 2022 | proactiveinvestors.comRace Oncology picks out Damian Clarke-Bruce to lead the company as it moves to ‘next stage of growth’December 8, 2022 | proactiveinvestors.com.auRace Oncology files human ethics application to commence cardioprotection breast cancer trial for ZantreneDecember 4, 2022 | proactiveinvestors.comRace Oncology appoints investment banker Daniel Sharp as independent non-executive directorNovember 24, 2022 | proactiveinvestors.com.auRace Oncology welcomes positive pre-IND meeting for ZantreneNovember 22, 2022 | proactiveinvestors.comRace Oncology receives positive guidance on Zantrene at pre-IND meeting with FDA; shares riseNovember 10, 2022 | proactiveinvestors.com.auRace Oncology farewells CMO and appoints interim replacement ahead of recruitment processOctober 17, 2022 | proactiveinvestors.com.auRace Oncology receives bull case valuation of A$6.1 billion in Pitt Street Research’s initiation reportOctober 16, 2022 | finance.yahoo.comWe're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To GrowSeptember 28, 2022 | proactiveinvestors.comRace Oncology expands potential market with improved IV formulation for cancer drug Zantrene®See More Headlines Receive RAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAC Company Calendar Last Earnings2/27/2019Today3/28/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:RAC CUSIPN/A CIKN/A Webwww.raceoncology.com Phone61 3 9097 1656FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.96% Return on Assets-18.51% Debt Debt-to-Equity RatioN/A Current Ratio33.90 Quick Ratio23.71 Sales & Book Value Annual Sales$1.38 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.29 Book ValueA$0.19 per share Price / BookN/AMiscellaneous Outstanding Shares161,310,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.61 Key ExecutivesMr. Phillip R. LynchCEO, MD & DirectorDr. Daniel TillettChief Scientific Officer & Exec. DirectorMs. Christina ManfreChief Financial OfficerDr. Ajay Duggal Dip Pharm MedMB ChB, MRCP, Interim Chief Medical OfficerMr. Peter Gordon Webse B.Bus (Age 59)FCIS, FCPA, FGIA, M.A.I.C.D., MAICD, Company Sec. Key Competitors3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CURAbattis BioceuticalsOTCMKTS:ATTBFAbcamOTCMKTS:ABCZFAbzenaLON:ABZAView All CompetitorsInsidersDaniel SharpSold 110,392 sharesTotal: $250,589.84 ($2.27/share)Daniel TillettBought 6,793 shares on 2/7/2023Total: $13,042.56 ($1.92/share)Daniel TillettBought 25,550 shares on 1/13/2023Total: $5.02 M ($196.57/share)Daniel TillettBought 46,737 shares on 12/20/2022Total: $99,175.91 ($2.12/share)Daniel TillettBought 2,307,925 shares on 11/14/2022Total: $475,432.55 ($0.21/share)View All Insider Transactions RAC Stock - Frequently Asked Questions How were Race Oncology's earnings last quarter? Race Oncology Limited (ASX:RAC) announced its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter. What other stocks do shareholders of Race Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX). What is Race Oncology's stock symbol? Race Oncology trades on the ASX under the ticker symbol "RAC." How much money does Race Oncology make? Race Oncology (ASX:RAC) has a market capitalization of $0.00 and generates $1.38 million in revenue each year. The company earns $-10,790,000.00 in net income (profit) each year or A($0.07) on an earnings per share basis. How can I contact Race Oncology? The official website for the company is www.raceoncology.com. The company can be reached via phone at 61 3 9097 1656. This page (ASX:RAC) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.